PLAQUE PSORIASIS

This study is testing an experimental drug called ORKA-001 for people with moderate-to-severe plaque psoriasis. Researchers want to see if the drug can completely clear skin symptoms and maintain that improvement over a year. The study involves 80 adults who will receive either t…

This study is testing an investigational oral medicine called JNJ-77242113 for people with moderate to severe plaque psoriasis. It aims to see if the new drug is more effective at clearing skin and reducing symptoms than a placebo (inactive pill) and how it compares to an existin…

This Phase 3 study is testing whether a daily oral tablet called ESK-001 can safely reduce the severity of moderate-to-severe plaque psoriasis. It will compare ESK-001 against a placebo (dummy pill) and an already-approved psoriasis medication (apremilast) in 840 adults. Particip…

This study is testing whether a new psoriasis medication called CT-P55 works as well as an already approved drug called Cosentyx. Researchers are comparing both treatments in 153 people with moderate to severe plaque psoriasis. The goal is to see which treatment better reduces sk…

This study is testing a cream called tapinarof for children with plaque psoriasis. It aims to see how safe the cream is and how much of the drug gets into the bloodstream when used daily. The trial involves kids aged 2 to 17 and includes an initial 12-week treatment period with a…

This study tested a daily pill called IRX4204 to see if it could safely improve skin symptoms in adults with mild to moderate plaque psoriasis. For 28 days, participants took either the drug or a placebo (inactive pill), and researchers compared their skin clearance and quality o…

This study is testing an investigational oral medicine called JNJ-77242113 for people with moderate to severe plaque psoriasis. It aims to see how well the new drug works and how safe it is compared to a placebo (inactive pill) and an approved injectable medicine called ustekinum…

This study is checking if a medication called ESK-001 is safe and keeps working for people with moderate-to-severe plaque psoriasis over a long period. It involves 1,680 adults who have already taken ESK-001 in a previous study. The research will see if the drug's benefits last a…

This study aims to check the long-term safety and effectiveness of an oral medication called TAK-279 for adults with moderate-to-severe plaque psoriasis. About 1,950 participants will take the drug for up to four years while doctors monitor for side effects and track skin improve…

This study is observing how well a medication called deucravacitinib works for adults with moderate-to-severe plaque psoriasis in everyday German clinics over five years. It will follow 550 patients who have already been prescribed the drug by their doctor to see how much their s…

This large, late-stage study is testing whether a daily pill called ESK-001 can safely reduce the severity of moderate-to-severe plaque psoriasis. It will compare ESK-001 against a placebo (dummy pill) and an already-approved psoriasis medication called apremilast. About 840 adul…

This study is testing whether the medication apremilast can safely and effectively reduce skin symptoms in Japanese children and teenagers (ages 6-17) who have moderate to severe plaque psoriasis. It involves 17 participants and will measure how much their skin clears up and how …

This study is testing how well a new oral medication, called JNJ-77242113, works for people with plaque psoriasis in sensitive areas like the scalp, genitals, palms, and soles of the feet. It will involve about 311 adults and adolescents whose psoriasis hasn't responded well to c…

This large, final-stage study is testing an investigational oral medication called JNJ-77242113 for people with moderate-to-severe plaque psoriasis. It aims to see if the new drug is more effective than a placebo (inactive pill) and how it compares to an existing approved treatme…

This study aims to see if a new oral medication called zasocitinib is more effective than an existing drug, deucravacitinib, for people with moderate-to-severe plaque psoriasis. About 606 participants will take daily pills for 16 weeks, with researchers measuring how much their s…

This study is testing an oral medication called JNJ-77242113 for people with moderate-to-severe plaque psoriasis. It aims to see how well the drug clears skin lesions, reduces symptoms like itch, and improves quality of life compared to a placebo. The trial will also monitor safe…

This study follows patients who have already tried the experimental drug ESK-001 in a previous trial. It aims to see how safe and effective the drug is when taken for a longer period of time to control plaque psoriasis. About 165 participants will continue taking one of two doses…

This study is checking the safety of the oral medication apremilast in children and teenagers with mild to moderate plaque psoriasis. It involves 51 participants aged 6 to 17 who have not been well-controlled with topical creams. The main goal is to monitor for side effects and s…